Core Viewpoint - North Chip Life Technology Co., Ltd. (stock code: 688712) has been listed on the Sci-Tech Innovation Board, raising nearly 1 billion yuan through the issuance of 57 million shares at a price of 17.52 yuan per share [1] Group 1: Financial Performance - The opening price of North Chip Life was 50.31 yuan, representing a 187% increase from the issuance price, with a market capitalization of 20.871 billion yuan at midday [3] - The company expects annual revenue between 520 million and 560 million yuan, reflecting a growth of 64.24% to 76.88% year-on-year [7] - Revenue for the first nine months of 2025 reached 407 million yuan, a 71.36% increase from 240 million yuan in the same period last year [7] - The projected net profit for the company in 2025 is between 78 million and 88 million yuan, indicating a year-on-year growth of 278.91% to 301.85% [7] Group 2: Company Overview - North Chip Life was established in 2015, focusing on cardiac interventional diagnostics, primarily developing, producing, and selling interventional and implantable medical devices [5] - The company’s FFR measurement system consists of the TruePhysio pressure microcatheter and the VivoCardio FFR measurement device, which aids in precise diagnosis and treatment of coronary artery disease [5] - The company reported revenues of 92.45 million yuan, 184 million yuan, and 317 million yuan for the years 2022, 2023, and 2024, respectively, with net losses of 300 million yuan, 155 million yuan, and 53.74 million yuan for the same years [5] Group 3: Shareholder Structure - Major investors include Sequoia Capital, Tiger Med, Qiming Venture Partners, and others, with Sequoia being the largest institutional shareholder [8] - Prior to the IPO, the actual controller, Song Liang, held 16.1530% of the shares directly and controlled an additional 13.414% through employee stock ownership platforms, totaling 29.5670% [8] - Post-IPO, Song Liang's direct shareholding decreased to 14.5377%, while Sequoia Capital's shareholding was reduced to 9.1583% [12][13]
北芯生命科创板上市：市值209亿，红杉与启明创投加持